Efficacy News and Research

RSS
Allos Therapeutics reports data from PROPEL trial of FOLOTYN in patients with PTCL

Allos Therapeutics reports data from PROPEL trial of FOLOTYN in patients with PTCL

Updated phase II study results of OPAXIO in patients with advanced esophageal cancer

Updated phase II study results of OPAXIO in patients with advanced esophageal cancer

Phase I study results of Pharmacyclics' PCI-32765 Btk inhibitor for B cell NHL presented at ASCO

Phase I study results of Pharmacyclics' PCI-32765 Btk inhibitor for B cell NHL presented at ASCO

Phase 3 trial demonstrates superiority of Amgen's denosumab over Zometa in preventing SREs

Phase 3 trial demonstrates superiority of Amgen's denosumab over Zometa in preventing SREs

Plexxikon announces Phase 1 extension study results of PLX4032 in metastatic colorectal cancer

Plexxikon announces Phase 1 extension study results of PLX4032 in metastatic colorectal cancer

Poniard reports positive data from Phase 3 SPEAR trial of picoplatin for SCLC

Poniard reports positive data from Phase 3 SPEAR trial of picoplatin for SCLC

Bright light therapy has significant effects on sleep disturbances associated with combat-related PTSD

Bright light therapy has significant effects on sleep disturbances associated with combat-related PTSD

bioTheranostics presents positive outcomes from CancerTYPE ID, Breast Cancer Index clinical studies

bioTheranostics presents positive outcomes from CancerTYPE ID, Breast Cancer Index clinical studies

AVEO's initiation of SCH 900105 Phase 2 trial in non-small cell lung cancer triggers $8.5M milestone payment

AVEO's initiation of SCH 900105 Phase 2 trial in non-small cell lung cancer triggers $8.5M milestone payment

ZymoGenetics' IL-21 Phase 2 clinical trial in metastatic melanoma meets primary endpoint

ZymoGenetics' IL-21 Phase 2 clinical trial in metastatic melanoma meets primary endpoint

Positive phase III clinical trial data of NovoCure's NovoTTF device for recurrent GBM presented at ASCO

Positive phase III clinical trial data of NovoCure's NovoTTF device for recurrent GBM presented at ASCO

Alder Biopharmaceuticals reports positive data from ALD518 Phase 2a clinical trial for NSCLC

Alder Biopharmaceuticals reports positive data from ALD518 Phase 2a clinical trial for NSCLC

Phase Ib/II trial data for trastuzumab-DM1 in combination with pertuzumab presented at ASCO 2010

Phase Ib/II trial data for trastuzumab-DM1 in combination with pertuzumab presented at ASCO 2010

Positive results from new analyses of denosumab Phase 3 trials

Positive results from new analyses of denosumab Phase 3 trials

Sleep apnea treatment remains effective between 31 and 53 months after beginning oral appliance therapy

Sleep apnea treatment remains effective between 31 and 53 months after beginning oral appliance therapy

Researchers assess influence of oral dimensions on MAS treatment success in patients with OSA

Researchers assess influence of oral dimensions on MAS treatment success in patients with OSA

New clinical research findings on oncology to be highlighted at ASCO 2010

New clinical research findings on oncology to be highlighted at ASCO 2010

USC to present promising new findings in cancer research at 2010 ASCO

USC to present promising new findings in cancer research at 2010 ASCO

Teva reports encouraging data from study assessing new lower-volume injection of Copaxone at 24th CMSC

Teva reports encouraging data from study assessing new lower-volume injection of Copaxone at 24th CMSC

Vandetanib in combination with chemotherapy improves progression-free survival in patients with lung cancer

Vandetanib in combination with chemotherapy improves progression-free survival in patients with lung cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.